Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in relapsed or refractory classical Hodgkin lymphoma and relapsed or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Berahyaluronidase Alfa (berahyaluronidase alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory | Phase 2 | Status: ACTIVE_NOT_RECRUITING